The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer

被引:9
作者
Bai, Xiaojing [1 ,2 ]
Jiang, Yumei [1 ,2 ]
Zhang, Xinwei [1 ,2 ]
Wang, Meiyu [3 ]
Tian, Juanhua [1 ]
Mu, Lijun [1 ]
Du, Yuefeng [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China
[2] Minist Educ, Oncol Res Lab, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Imaging, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
基金
中国国家自然科学基金;
关键词
total prostate-specific antigen; free prostate-specific antigen; prostate-specific antigen density; prostate cancer; benign prostatic hyperplasia; FREE ELECTROCHEMICAL IMMUNOSENSOR; DIGITAL RECTAL EXAMINATION; ULTRASOUND-GUIDED BIOPSY; MULTI-PARAMETRIC MRI; MAGNETIC-RESONANCE; HIGH-RISK; NG/ML; PSA; MEN; COMPLICATIONS;
D O I
10.2147/CMAR.S257769
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Methods: From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data. Results: Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4-20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4-20 ng/mL, the fPSA/ TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio <= 0.15 and the PSAD >= 0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively. Conclusion: When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio <= 0.15 and a PSAD >= 0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH.
引用
收藏
页码:6821 / 6826
页数:6
相关论文
共 50 条
[31]   Classifying prostate cancer patients based on total prostate-specific antigen and free prostate-specific antigen features by support vector machine [J].
Nguyen Thi Hong Nhung ;
Vu Tran Minh Khuong ;
Vu Quang Huy ;
Pham The Bao .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) :818-825
[32]   Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later [J].
Pienta, Kenneth J. .
UROLOGY, 2009, 73 (5A) :11-20
[33]   Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands [J].
Jyoti, Shravana Kumar ;
Blacke, Camille ;
Patil, Pallavi ;
Amblihalli, Vibha P. ;
Nicholson, Amanda .
CANCER CAUSES & CONTROL, 2018, 29 (01) :87-92
[34]   Evaluation of magnetic resonance imaging-based prostate-specific antigen density of the prostate in the diagnosis of prostate cancer [J].
Hoshii, Tatsuhiko ;
Nishiyama, Tsutomu ;
Toyabe, Shinichi ;
Akazawa, Kohei ;
Komatsu, Shuichi ;
Kaneko, Masaaki ;
Hara, Noboru ;
Takahashi, Kota .
INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (04) :305-310
[35]   Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer [J].
Botchorishvili, George ;
Matikainen, Mika P. ;
Lilja, Hans .
CURRENT OPINION IN UROLOGY, 2009, 19 (03) :221-226
[36]   Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men [J].
Ghafoori, Mahyar ;
Varedi, Peyman ;
Hosseini, Seyed Jalil ;
Asgari, Mojgan ;
Shakiba, Madjid .
UROLOGY JOURNAL, 2009, 6 (03) :182-188
[37]   Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence [J].
Wilt, Timothy J. ;
Scardino, Peter T. ;
Carlsson, Sigrid V. ;
Basch, Ethan .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (03)
[38]   Prostate-specific antigen screening and mortality from prostate cancer [J].
Marcella, Stephen W. ;
Rhoads, George G. ;
Carson, Jeffrey L. ;
Merlino, Frances ;
Wilcox, Homer .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (03) :248-253
[39]   Recommendations on screening for prostate cancer with the prostate-specific antigen test [J].
Bell, Neil ;
Gorber, Sarah Connor ;
Shane, Amanda ;
Joffres, Michel ;
Singh, Harminder ;
Dickinson, James ;
Shaw, Elizabeth ;
Dunfield, Lesley ;
Tonelli, Marcello .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (16) :1225-1234
[40]   Usefulness of prostate-specific antigen velocity in screening for prostate cancer [J].
Ito, K ;
Yamamoto, T ;
Ohi, M ;
Kubota, Y ;
Fukabori, Y ;
Kurokawa, K ;
Suzuki, K ;
Yamanaka, H .
INTERNATIONAL JOURNAL OF UROLOGY, 2002, 9 (06) :316-321